BACKGROUND: Enterohepatic recirculation of irinotecan and one of its metabolites, SN-38, has been observed in pharmacokinetic data sets from previous studies. A mathematical model that can incorporate this phenomenon was developed to describe the pharmacokinetics of irinotecan and its metabolites. PATIENTS AND METHODS: A total of 32 patients with recurrent malignant glioma were treated with weekly intravenous administration of irinotecan at a dose of 125 mg/m(2). Plasma concentrations of irinotecan and its three major metabolites were determined. Pharmacokinetic models were developed and tested for simultaneous fit of parent drug and metabolites, including a recirculation component. RESULTS: Rebound in the plasma concentration suggestive of enterohepatic recirculation at approximately 0.5-1 h post-infusion was observed in most irinotecan plasma concentration profiles, and in some plasma profiles of the SN-38 metabolite. A multi-compartment model containing a recirculation chain was developed to describe this process. The recirculation model was optimal in 22 of the 32 patients compared to the traditional model without the recirculation component. CONCLUSION: A recirculation chain incorporated in a multi-compartment pharmacokinetic model of irinotecan and its metabolites appears to improve characterization of this drug's disposition in patients with glioma.
BACKGROUND: Enterohepatic recirculation of irinotecan and one of its metabolites, SN-38, has been observed in pharmacokinetic data sets from previous studies. A mathematical model that can incorporate this phenomenon was developed to describe the pharmacokinetics of irinotecan and its metabolites. PATIENTS AND METHODS: A total of 32 patients with recurrent malignant glioma were treated with weekly intravenous administration of irinotecan at a dose of 125 mg/m(2). Plasma concentrations of irinotecan and its three major metabolites were determined. Pharmacokinetic models were developed and tested for simultaneous fit of parent drug and metabolites, including a recirculation component. RESULTS: Rebound in the plasma concentration suggestive of enterohepatic recirculation at approximately 0.5-1 h post-infusion was observed in most irinotecan plasma concentration profiles, and in some plasma profiles of the SN-38 metabolite. A multi-compartment model containing a recirculation chain was developed to describe this process. The recirculation model was optimal in 22 of the 32 patients compared to the traditional model without the recirculation component. CONCLUSION: A recirculation chain incorporated in a multi-compartment pharmacokinetic model of irinotecan and its metabolites appears to improve characterization of this drug's disposition in patients with glioma.
Authors: L Iyer; C D King; P F Whitington; M D Green; S K Roy; T R Tephly; B L Coffman; M J Ratain Journal: J Clin Invest Date: 1998-02-15 Impact factor: 14.808
Authors: H S Friedman; W P Petros; A H Friedman; L J Schaaf; T Kerby; J Lawyer; M Parry; P J Houghton; S Lovell; K Rasheed; T Cloughsey; E S Stewart; O M Colvin; J M Provenzale; R E McLendon; D D Bigner; I Cokgor; M Haglund; J Rich; D Ashley; J Malczyn; G L Elfring; L L Miller Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: Rami G Azrak; Jinsheng Yu; Lakshmi Pendyala; Patrick F Smith; Shousong Cao; Xia Li; William D Shannon; Farukh A Durrani; Howard L McLeod; Youcef M Rustum Journal: Mol Cancer Ther Date: 2005-05 Impact factor: 6.261
Authors: Michael D Prados; W K A Yung; Kurt A Jaeckle; H Ian Robins; Minesh P Mehta; Howard A Fine; Patrick Y Wen; Timothy F Cloughesy; Susan M Chang; M Kelly Nicholas; David Schiff; Harry S Greenberg; Larry Junck; Karen L Fink; Kenneth R Hess; John Kuhn Journal: Neuro Oncol Date: 2004-01 Impact factor: 12.300
Authors: A P Venook; C Enders Klein; G Fleming; D Hollis; C G Leichman; R Hohl; J Byrd; D Budman; M Villalona; J Marshall; G L Rosner; J Ramirez; H Kastrissios; M J Ratain Journal: Ann Oncol Date: 2003-12 Impact factor: 32.976
Authors: A R Clamp; J Mäenpää; D Cruickshank; J Ledermann; P M Wilkinson; R Welch; S Chan; P Vasey; B Sorbe; A Hindley; G C Jayson Journal: Br J Cancer Date: 2006-01-16 Impact factor: 7.640
Authors: Alexander K Berg; Jan C Buckner; Evanthia Galanis; Kurt A Jaeckle; Matthew M Ames; Joel M Reid Journal: J Clin Pharmacol Date: 2015-06-26 Impact factor: 3.126
Authors: Tae Hwan Kim; Soyoung Shin; Cornelia B Landersdorfer; Yong Ha Chi; Soo Heui Paik; Jayhyuk Myung; Rajbharan Yadav; Stefan Horkovics-Kovats; Jürgen B Bulitta; Beom Soo Shin Journal: AAPS J Date: 2015-05-20 Impact factor: 4.009
Authors: Femke M de Man; Andrew K L Goey; Ron H N van Schaik; Ron H J Mathijssen; Sander Bins Journal: Clin Pharmacokinet Date: 2018-10 Impact factor: 6.447